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Exercise duration (in seconds) by exercise test and QOL score
assessment by Kansas City Cardiomyopathy Questionnaire
(KCCQ) and Serum BNP level. In ivabradine group, patients were
started on ivabradine5 mg in twice daily dose, in addition to OMT.
Patients were followed up for 6 months. At the end of six months,
LV dimensions, LV function, serum BNP levels, QOL and exercise
duration were re-assessed.
Results: At six months, though there was significant reduction of
heart rate (70.60 ± 5.06 vs 91.33 ±8.9, p < 0.0001) and improvement
of QOL score (p¼ 0.004) and NYHA functional Class(p¼ 0.007) with
ivabradine group compared to OMT group, ivabradine failed to
show significant improvement in LVEF(35 ±3.71 vs 33±4.24, p¼NS),
Exercise duration (320 ±130.6 vs 311.79 ±103.60, p¼ 0.663) and BNP
level (248.64 ±175.70 vs 312.57 ±222.6, p¼ 0.22). Subgroup analysis
showed significant improvement in LVEF (35.71±2.98 vs 33.50
±3.73, p¼0.003) in patients with ivabradine who achieved heart
rate less than 70(n¼25). No significant adverse effects on ivabra-
dine therapy were noted at the end of six months.
Conclusions: Ivabradine when added to optimal medical therapy,
in NYHA Functional Class and QoL in patients with ischemic heart
failure. Improvement of Left ventricular function also occurs in
presence of adequate heart rate lowering (HR<70/ min).
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Background: Levosimendan, a calcium channel sensitiser, im-
proves myocardial contractility without causing an increase in
myocardial oxygen demand. This study was done to compare the
effects of levosimendan and dobutamine on clinical outcome in
patients with low-output heart failure.
Methods: Patients were eligible for participation in this study if
they had symptomatic low output heart failure. Overall 175 pa-
tients were enrolled in this study. Under continuous haemody-
namic monitoring, an initial loading dose of levosimendan of 24
mcg/kg was infused over 10 min, followed by a continuous infu-
sion of 0.1 mcg/kg/min for 24 h. Dobutamine was infused for 24 h
at a dose of 5 mcg/kg/min. The primary endpoint was the pro-
portion of patients with clinical improvement.
Results: 100 patients were given levosimendan and 75 dobut-
amine. The clinical improvement was achieved in 28 (28%) levo-
simendan-group patients and 15 (20%) in the dobutamine group
p¼0.02). At 6 months, 20 (20%) levosimendan-group patients had
died, compared with 25 (33%) in the dobutamine group p¼0.02).
Conclusion: In patients with severe, low-output heart failure,
levosimendan improved clinical outcome more effectively than
dobutamine. Lower mortality was noted in levosimendan group
upto 6 months.
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Background: A cardiac syndrome of “apical ballooning” is being
increasingly encountered in routine cardiology practice as it
usually mimics acute coronary syndrome at presentation and
therefore mandates demonstration of non critical coronary artery
disease on coronary angiogram for diagnostic confirmation but its
feasibility is scarce in our country. We sought to assimilate clin-
ical, echo-cardiographic and angiographic features of this syn-
drome at a tertiary care setting from carefully selected cases of
apical ballooning and develop an algorithmwhich should help the
emergency physician in making a simpler bedside diagnosis of
this syndrome.
Methods: Patients apparently admitted with acute coronary syn-
drome but subsequently given the diagnosis of transient LV apical
ballooning syndrome at our institution from January 2011 to June
2013 were taken prospectively.
Results: Twelve patients were enrolled, mean age was 50±12
years, 10 (83%) were women. Trigger events could be identified in
9(75%) patients (emotional stress in 3 (25%),post vocal cord sur-
gery in 1(8%), hemiarthroplasty in 1(8%), cervical spine surgery in
1(8%), cervical trauma in 1(8%), gastrointestinal infection in 1 (8%),
road side accident in 1(8%). Presenting symptomswere; chest pain
or discomfort in 3 (25%), NYHA grade III/IV dyspnoea in 9(75 %)
patients. 7 (58%) patients had elevated creatine kinase MB and
troponin T levels, but the levels were usually only marginally
elevated. Electrocardiographic changes observed were ST-
segment elevation in 3 (25%), pathological Q waves in 3(25%),
mainly in the leads V1-4.ST-segment depression was found in 4
patients (30%),3 patients (25%) exhibited T-wave inversion
without ST-segment shift.3 patients presented with cardiogenic
shock and 1 patient with ventricular tachycardia. Echocardio-
graphic parameters mean ± SD LV end-diastolic volume was
(115.9±4.0 mL) mean ± SD LV ejection fraction was (28.2%±2.5%).
None of the patients had an E/Em ratio of more than 15. In all 12
patients, left ventricular systolic function recovered completely
within three weeks. The systolic strain rate was decreased from
base to apex, but the early diastolic strain rate from base to apex
was marginally reduced (+3±0.5).
Conclusion: In patients with suspected ABS, clinical history of
acute physical/emotional stress with ECG changes mimicking
ischemia/infarct, echocardiographic systolic/diastolic paradox
with or without contrast echocardiography is helpful in catego-
rization of these patients.
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Background: Ivabradine is a drug which acts by selectively
blocking If current in the SA Node. It is approved for use in chronic
congestive heart failure. In patients with acute decompensated
systolic heart failure, tachycardia could be either a compensatory
mechanism or contribute to worsening heart failure. There are
situations where using a beta blocker is not an option.The present
study was planned to assess the feasibility, safety and efficacy of
using Ivabradine in acute heart failure.
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